Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of ITI-214 in Patients With Heart Failure
| Status: | Recruiting |
|---|---|
| Conditions: | Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - 80 |
| Updated: | 7/28/2018 |
| Start Date: | July 10, 2018 |
| End Date: | December 2019 |
| Contact: | Kimberly Vanover, PhD |
| Email: | itciclinicaltrials@intracellulartherapies.com |
| Phone: | 646-440-9333 |
Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of Escalating Single Doses of ITI-214 in Patients With Systolic Heart Failure
This is a Phase I/II randomized, double-blind, placebo-controlled, single rising dose study
in patients with systolic heart failure to evaluate the safety and tolerability of ITI-214.
in patients with systolic heart failure to evaluate the safety and tolerability of ITI-214.
Inclusion Criteria:
- NYHA class II-III heart failure
- Ejection fraction equal to or below 35%
- On stable heart failure drug treatment
Exclusion Criteria:
- Considered medically inappropriate for study participation
We found this trial at
2
sites
3400 N Charles St
Baltimore, Maryland 21205
Baltimore, Maryland 21205
410-516-8000
Principal Investigator: Nisha Gilotra, MD
Johns Hopkins University The Johns Hopkins University opened in 1876, with the inauguration of its...
Click here to add this to my saved trials
Click here to add this to my saved trials